Lung Cancer | Specialty

The lung cancer condition center is a comprehensive resource for clinical news and expert insights on lung cancer. Read more at OncLive.

Q2 2025: 7 FDA Decisions to Watch in the Realm of Oncology

April 5th 2025

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Dr Herzberg on the Distinctions Between Sotorasib and Adagrasib for KRAS G12C+ NSCLC

April 4th 2025

Benjamin Herzberg, MD the clinical similarities and key distinctions between sotorasib and adagrasib for KRAS G12C+ NSCLC.

Perioperative Durvalumab-Based Regimen Receives European Approval for Resectable NSCLC

April 4th 2025

Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.

Dr Herzberg on Notable Ongoing Research in KRAS-Mutated NSCLC

April 2nd 2025

Benjamin Herzberg, MD, discusses current and future research efforts in KRAS-mutated NSCLC.

Pembrolizumab Plus cCRT Elicits Durable Antitumor Activity in Unresectable Stage III NSCLC

April 1st 2025

Updated KEYNOTE-799 data continued to show robust activity with pembrolizumab plus concurrent chemoradiation in unresectable stage III NSCLC.

Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC

March 31st 2025

Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.

CAN-2049 Displays Potential OS Benefit in Advanced NSCLC After Inadequate Response to Checkpoint Inhibitors

March 31st 2025

CAN-2049 plus prodrug and continued immune checkpoint inhibition showed a potential OS benefit in advanced non–small cell lung cancer.

Tislelizumab Plus Chemo Receives Positive CHMP Opinion for ES-SCLC

March 31st 2025

The EMA’s CHMP recommended the approval of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer.

Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC

March 31st 2025

Panelists discuss how, if the MARIPOSA trial shows an overall survival advantage exceeding 1 year, the amivantamab-lazertinib combination may see increased frontline use. Subsequent therapy options could include chemotherapy, targeted therapies based on resistance mechanisms, or clinical trials for emerging treatments.

Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC

March 31st 2025

Panelists discuss how medical professionals consider continuing osimertinib with second-line and subsequent therapies based on disease progression, resistance mechanisms, and patient response. It may be combined with other agents or switched depending on clinical trials, biomarkers, and overall treatment goals to optimize outcomes.

The OncFive: Top Oncology Articles for the Week of 3/23

March 29th 2025

The FDA cleared therapeutic options in pNETs/epNETs, MIBC, and mCRPC; experts highlight top abstracts ahead of 2025 EBMT; and more from OncLive.

CHMP Offers Positive Opinion for Perioperative Nivolumab Plus Chemo in Resectable PD-L1+ NSCLC

March 28th 2025

The EMA’s CHMP has recommended the approval of perioperative nivolumab plus chemotherapy in resectable PD-L1–positive non–small cell lung cancer.

Tailoring Immunotherapy Strategies for the Advanced NSCLC

March 28th 2025

Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.

The Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

March 28th 2025

Panelists discuss how emerging data on novel HER2-targeted agents, including Beamion LUNG-1 (zongertinib) and SOHO-1 (BAY 2927088), show promise for advanced non–small cell lung cancer (NSCLC). Additionally, the eNRGy trial and FDA approval of zenocutuzumab for NRG1 fusion–positive non–small cell lung cancer (NSCLC) offers new treatment avenues. Patient selection will depend on genetic profiling and treatment efficacy.

Frontline Fulzerasib Plus Cetuximab Elicits Deep, Durable Responses in KRAS G12C–Mutated NSCLC

March 28th 2025

Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Adagrasib Combo Continues to Show Efficacy in KRAS G12C–Mutated NSCLC and PD-L1 ≥50%

March 28th 2025

Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Tailoring Immunotherapy Strategies for Advanced NSCLC

March 28th 2025

Panelists discuss how treatment decisions for advanced non–small cell lung cancer (NSCLC) without actionable mutations depend on factors like PD-L1 status, histology (eg, squamous [SQ]), and biomarkers like STK11/KEAP1. Chemotherapy may be added based on individual patient factors, with promising advancements expected in 2025.

Recent Updates in the Management Advanced NSCLC with HER2 or NRG1 Alterations

March 28th 2025

Panelists discuss how emerging data on novel HER2-targeted agents, including Beamion LUNG-1 (zongertinib) and SOHO-1 (BAY 2927088), show promise for advanced non–small cell lung cancer (NSCLC). Additionally, the eNRGy trial and FDA approval of zenocutuzumab for NRG1 fusion–positive non–small cell lung cancer (NSCLC) offers new treatment avenues. Patient selection will depend on genetic profiling and treatment efficacy

Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC

March 27th 2025

Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.

KRAS G12C and Beyond: KRAS Targeted Agents of Interest Under Development in NSCLC

March 25th 2025

Benjamin Herzberg, MD, highlights novel therapies in the KRAS-mutated NSCLC landscape and ongoing questions research is seeking to answer in this space.

NEXT PAGE
PREVIOUS PAGE